Skip to main content
Innoviva, Inc. logo

Innoviva, Inc. — Investor Relations & Filings

Ticker · INVA ISIN · US45781M1018 LEI · 549300ACOX4QTBES6535 US Financial and insurance activities
Filings indexed 1,226 across all filing types
Latest filing 2011-06-17 Director's Dealing
Country US United States of America
Listing US INVA

About Innoviva, Inc.

https://www.inva.com/

Innoviva, Inc. is a diversified holding company that manages a portfolio of royalty-generating assets and operates a commercial-stage biopharmaceutical platform. The company's core royalty business is centered on respiratory therapies, providing a stable cash flow. Through its subsidiary, Innoviva Specialty Therapeutics, it focuses on developing and commercializing innovative treatments for patients in critical care and with infectious diseases. Innoviva's strategy involves leveraging its financial assets to invest in healthcare opportunities with high unmet medical needs, aiming to advance differentiated therapies and build a diverse portfolio of healthcare assets.

Recent filings

Filing Released Lang Actions
4 Filing
Director's Dealing
2011-06-17 English
4 Filing
Director's Dealing
2011-06-16 English
4 Filing
Director's Dealing
2011-06-16 English
4 Filing
Director's Dealing
2011-06-08 English
8-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce significant events. The text indicates it includes a press release about Phase 3 study results and mentions a conference call. The document length is 2632 characters, which is relatively short and mainly contains an announcement and a press release. There are no detailed financial statements or comprehensive financial analysis present. The document is not an earnings release (ER) because it is a press release about clinical study results, not financial results. It is not a call transcript (CT) because it only mentions a call will happen, not the transcript itself. The document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit into more specific categories like earnings release or management report. The presence of a press release as an exhibit supports this classification rather than a full report type.
2011-06-02 English
4 Filing
Director's Dealing
2011-06-01 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.